Homology Medicines Inc. Stock News

Goldman Sachs Group Inc. grew its holdings in Homology Medicines, Inc. (NASDAQ:FIXX) by 457.7% during the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 250,883 shares of the companys stock after purchasing an additional 205,896 shares during the period. Goldman Sachs Group Inc.s []

UBS Asset Management Americas Inc. increased its position in shares of Homology Medicines, Inc. (NASDAQ:FIXX) by 127.9% in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 80,904 shares of the companys stock after purchasing an additional 45,404 shares during []

Homology Medicines, Inc. (NASDAQ:FIXX) has earned a consensus rating of “Buy” from the six research firms that are covering the stock, MarketBeat reports. Two equities research analysts have rated the stock with a hold recommendation and four have issued a buy recommendation on the company. The average 12 month target price among brokers that have […]

Price T Rowe Associates Inc. MD lessened its holdings in Homology Medicines, Inc. (NASDAQ:FIXX) by 15.9% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 2,264,659 shares of the companys stock after selling 427,002 shares during the period. Price T []

- Achieved Goal of Three Clinical Programs Across Gene Therapy and Gene Editing Technology Platform This Year -

Homology Medicines has built a unique gene therapy platform but has experienced a significant stock price decrease due to a COVID-related trial delay and controversy over its gene editing applications

- juMPStart Trial to Evaluate First Systemic Gene Therapy Candidate for Patients with Hunter Syndrome -

Investors need to pay close attention to Homology Medicines (FIXX) stock based on the movements in the options market lately.

Homology Medicines (FIXX) delivered earnings and revenue surprises of 6.90% and 249.92%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

- On Track to Report Initial Phase 2 Data From pheNIX PKU Clinical Trial by Year End -

- Data From Company's PKU and Hunter Syndrome Gene Therapy Programs Featured in Presentations -

- Built Internal GMP Commercial Process and Manufacturing Platform and Scaled HEK293 Suspension System to 2,000L Under His Leadership -

Dilution is on the way thanks to the company's latest stock offering.

BEDFORD, Mass., April 07, 2021 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (Nasdaq: FIXX), a clinical-stage genetic medicines company, today announced the pricing of an underwritten public offering